P010 5-AMINOSALICYLATES (5-ASAS) AND RENAL FUNCTION IN INFLAMMATORY BOWEL DISEASE (IBD): A SYSTEMATIC REVIEWdoi:10.1016/S1873-9954(07)70022-8J.P.GisbertandY.Gonzalez-LamaandJ.MateSDOSJournal of Crohns & Colitis Supplements
Neither sulfasalazine nor mesalamine were effective in preventing quiescent CD relapse, but in a per protocol analysis mesalamine appeared to reduce risk of relapse (RR=0.79; 95% CI=0.66-0.95, NNT=13).CONCLUSIONS:The role of 5-ASAs in inducing remission of active CD and preventing relapse of ...
5-Aminosalicylates (5-ASAs) may prevent some UC-associated CRC. Therefore, in patients prescribed 5-ASAs for maintenance of remission, annual surveillance might be overly burdensome and inefficient. We aimed to determine the ideal frequency of surveillance in patients with UC maintained on 5-ASAs...
Both serum creatinine levels and ClCr were similar in patients with and without 5-ASA treatment, and remained stable throughout the 4-year follow-up in patients taking 5-ASAs. In the multivariate analysis, 5-ASA treatment (or its dose) was not correlated with serum creatinine levels or Cl...
5-aminosalicylates5-ASAsinflammatory bowel diseaseulcerative colitisnetworkmeta-analysis.Background: 5-aminosalicylates (5-ASAs) are the mainstay of treatment for mild to moderately active ulcerative colitis (UC). The optimum 5-ASA preparation, dosedoi:10.2139/ssrn.3680606Brigida Barberio...
Eligible trials recruited adults with active or quiescent CD and compared 5-ASAs with placebo, or no treatment. Dichotomous data were pooled to obtain relative risk (RR) of failure to achieve remission in active CD, and RR of relapse of disease activity in quiescent CD, with a 95% ...
Adverse effects, toxicities, drug interactions, contraindications, and pregnancy categories of these agents is summarized. Lastly, this chapter highlights the studies that examined the clinical efficacy of 5-ASAs in ulcerative colitis and Crohn's disease.M. Michael Wolfe MD...
Efficacy of 5-aminosalicylic acids (5-ASAs) in ulcerative colitis (UC) has been studied previously in meta-analyses. However, no recent meta-analysis has studied the relative efficacies of differing routes of administration.MEDLINE, EMBASE, and the Cochrane central register of controlled ...
These effects were completely reversed by GW9662, a PPAR纬 antagonist (p=0.006). The in vivo profile of lipid mediators in HC treated with 5-ASAs differed from UC, with subtle differences in resolving inflammatory cellular and cytokine constituents; this has important implications for understanding...
Adjusted odds ratios were calculated by the Mantel-Haenszel methodology.Among 1,552,109 women, 3651 with 3721 infants had reported the use of 5-ASAs in early pregnancy. The risk of a major malformation was increased (1.37, 95% confidence interval = 1.17-1.62) and still more for a ...